# Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

> **NCT03789552** · PHASE3 · RECRUITING · sponsor: **Tasly Pharmaceuticals, Inc.** · enrollment: 765 (estimated)

## Conditions studied

- Chronic Stable Angina Pectoris

## Interventions

- **DRUG:** T89 capsule
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT03789552
- **Lead sponsor:** Tasly Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 765 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789552, "Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03789552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*